Related references
Note: Only part of the references are listed.Short-term safety of mTOR inhibitors in infants and very young children with tuberous sclerosis complex (TSC): Multicentre clinical experience
Darcy A. Krueger et al.
EUROPEAN JOURNAL OF PAEDIATRIC NEUROLOGY (2018)
Everolimus for treatment-refractory seizures in TSC: Extension of a randomized controlled trial
David N. Franz et al.
NEUROLOGY-CLINICAL PRACTICE (2018)
mTOR Signaling in Growth, Metabolism, and Disease
Robert A. Saxton et al.
CELL (2017)
Long-term treatment of epilepsy with everolimus in tuberous sclerosis
Darcy A. Krueger et al.
NEUROLOGY (2016)
Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study
David N. Franz et al.
PLOS ONE (2016)
mTOR inhibitors and diabetes
Bruno Verges et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2015)
Metabolic complications with the use of mTOR inhibitors for cancer therapy
Shanthi Sivendran et al.
CANCER TREATMENT REVIEWS (2014)
Everolimus for subependymal giant cell astrocytoma in patients with tuberous sclerosis complex: 2-year open-label extension of the randomised EXIST-1 study
David Neal Franz et al.
LANCET ONCOLOGY (2014)
Everolimus long-term safety and efficacy in subependymal giant cell astrocytoma
Darcy A. Krueger et al.
NEUROLOGY (2013)
Management of Metabolic Effects Associated With Anticancer Agents Targeting the PI3K-Akt-mTOR Pathway
Naifa L. Busaidy et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Management of Side Effects of Sirolimus Therapy
Giovanni Stallone et al.
TRANSPLANTATION (2009)
mTOR inhibition by rapamycin prevents β-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes
Merav Fraenkel et al.
DIABETES (2008)
The tuberous sclerosis complex
Peter B. Crino et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Share Paper
